Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$1.53 USD
+0.01 (0.66%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.52 -0.01 (-0.65%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
ATOS 1.53 +0.01(0.66%)
Will ATOS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATOS
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATOS
Promising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer Treatment
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Atossa Therapeutics, Quantum Leap announces initiation of I-SPY 2 trial
Video: Friday 4/12 Insider Buying Report: ATOS, TRDA
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference